EVALUATION OF BACTERIAL RESISTANCE OF CEFADROXIL, CEPHALEXIN AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE MICRO-ORGANISMS

Authors

  • S SUNDAR Department of Biotechnology, Vijaya Institute of Pharmaceutical Sciences for Women, Vijayawada, Andhra Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i5.37319

Keywords:

Bacterial resistance, Cefadroxil, Cephalexin, Agar disk diffusion

Abstract

Objective: This study was aimed to overcome the problems of bacterial resistance to antibiotics used for the treatment of diseases.

Methods: In this aspect, two antibiotics were selected such as cefadroxil and cephalexin for the evaluation of antibiotic resistance against selected three Gram-positive microorganisms such as Bacillus subtilis, Staphylococcus aureus, and Bacillus cereus and three Gram-negative microorganisms such as E. coli, Pseudomonas aeruginosa, and Serratia marcescens. The selected antibiotics were evaluated by the determination of minimum inhibitory concentration and the agar disk diffusion method.

Results: According to the results obtained, cefadroxil was resistant against Bacillus cereus (25.6 μg/ml, 10 mm) and Serratia marcescens (25.6, 6 mm), sensitive against Pseudomonas aeruginosa (6.4 μg/ml, 18 mm), Bacillus subtilis (6.4 μg/ml, 30 mm), intermediate against E. coli (12.8 μg/ml, 16 mm), and Staphylococcus aureus (12.8 μg/ml, 15 mm). Similarly, cephalexin was resistant against Serratia marcescens (25.6 μg/ml, 10 mm), intermediate against E. coli (12.8 μg/ml, 14 mm), Pseudomonas aeruginosa (25.6 μg/ml, 14 mm), Bacillus subtilis (12.8 μg/ml, 15 mm), Staphylococcus aureus (6.4 μg/ml, 16 mm), and sensitive against Bacillus cereus (6.4 μg/ml, 18 mm) according to the CLSI report.

Conclusion: The increased illness of human beings by the usage of antibiotics frequently without prescriptions is a serious problem that dramatically raises the cost of health-care worldwide. Hence, the study was useful and effective for the determination of antibiotic resistance of cephalexin and cefadroxil for the future treatment in more efficacies with fewer side effects.

Downloads

Download data is not yet available.

References

Zoorob R, Sidani MA, Fremont RD, Kihlberg C. Antibiotic use in acute upper respiratory tract infections. Am Fam Physician 2012;86:817-22. PMID 23113461.

WHO. Prevention and Control of Acute Respiratory Infections (ARIs) Tend to Become Acute Respiratory Diseases in Health Care. Geneva: WHO Interim Guideline; 2007.

Kasim LS. Bioavailability and bioequivalence. Public lecture delivered at Mandatory Continue Pharmacists Development. Module 2009;4:15-7.

Worokarti. The Role of Pharmacists in Patient Management of Infectious Disease Incidence to Prevent antimicrobial Resistance, Complete manuscripts Symposium on Infectious Diseases and the Problem of antimicrobial Resistance, Amrin. Surabaya; 2005. p. 55-69.

Nakagawa T, Haginaka J, Yamaoka K, Uno T. High speed liquid chromatographic determination of cephalexin in human plasma and urine. J Antibiot (Tokyo) 1978;31:769-75. doi: 10.7164/ antibiotics.31.769, PMID 690010.

Campins-Falco P, Sevillano-Cabeza A, Gallo-Martinez L, Bosch-Reig F, Monzo-Mansanet I. Comparative study on the determination of cephalexin in its dosage forms by spectrophotometry and HPLC with UV–vis detection. Mikrochim Acta 1997;126:207-15. doi: 10.1007/ BF01242322.

Rebuelto M, Montoya L, Kreil V, Ambros L, Waxman S, Albarellos G, et al. Pharmacokinetics of two once-daily parenteral cephalexin formulations in dogs. J Vet Pharmacol Ther 2005;28:419-23. doi: 10.1111/j.1365-2885.2005.00676.x, PMID 16207303.

Prados AP, Schaiquevich P, Kreil V, Monfrinotti A, Quaine P, Tarragona L, et al. A population pharmacokinetic approach to describe cephalexin disposition in adult and aged dogs. Vet Med Int 2014;2014:789353. doi: 10.1155/2014/789353, PMID 25431741.

Katzung BG, Masters SB, Trevor AJ. Basic and Clinical Pharmacology. New York: McGraw-Hill Medical; 2009.

Tripathi KD. Beta-Lactam Antibiotics. Essentials of Medical Pharmacology. 6th ed. New Delhi: Jaypee Brothers; 2008. p. 705.

Goldfarb J, Crenshaw D, O’Horo J, Lemon E, Blumer JL. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrob Agents Chemother 1988;32:1780-3. doi: 10.1128/ AAC.32.12.1780, PMID 3149884.

McLinn S. A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. J Am Acad Dermatol 1990;22 (5 Pt 1):883-5. doi: 10.1016/0190-9622(90)70118-2, PMID 2112166.

Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966;45:493-6. doi: 10.1093/ajcp/45.4_ts.493, PMID 5325707.

Published

07-05-2022

How to Cite

SUNDAR, S. “EVALUATION OF BACTERIAL RESISTANCE OF CEFADROXIL, CEPHALEXIN AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE MICRO-ORGANISMS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 15, no. 5, May 2022, pp. 54-57, doi:10.22159/ajpcr.2022.v15i5.37319.

Issue

Section

Original Article(s)